Dendritic polylysine co-delivery of paclitaxel and siAXL enhances the sensitivity of triple-negative breast cancer chemotherapy

被引:1
|
作者
Wan, Xiaofeng [1 ]
Chen, Chuanrong [2 ]
Zhan, Jianmin [1 ]
Ye, Shuke [1 ]
Li, Runsheng [1 ]
Shen, Ming [1 ]
机构
[1] Shanghai Inst Biomed & Pharmaceut Technol, Natl Hlth Commiss NHC, Key Lab Reprod Regulat, Shanghai, Peoples R China
[2] Yijishan Hosp, Dept Oncol, Wannan Med Coll, Wuhu, Peoples R China
基金
中国国家自然科学基金;
关键词
dendritic polylysine; siRNA delivery; tumor microenvironment sensitivity; drug resistance; triple-negative breast cancer; EXTRACELLULAR PH; RESISTANCE; AXL; SYSTEM; TUMORS;
D O I
10.3389/fbioe.2024.1415191
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Drug resistance is common in triple-negative breast cancer (TNBC) therapy. To identify a method to overcome chemotherapy resistance in TNBC cells, an siRNA targeting the AXL gene (siAXL), which can overcome drug resistance, was used in this study. A nanodelivery system was constructed to co-deliver siAXL and paclitaxel (PTX).Methods: A biodegradable and tumor microenvironment (TME)-sensitive mPEG-coated dendritic polylysine material (PDPLL) was synthesized. This material was used to construct single-molecule nanoparticles to co-deliver PTX and siAXL. The drug encapsulation and morphological properties of the nanoparticles (NPs) were characterized. The sensitivity of the NPs to the TME was evaluated in vitro with a dialysis method. The tumor-targeting effect of the PDPLL NPs was evaluated by fluorescence imaging and drug distribution evaluation in vivo. The ability to overcome drug resistance was evaluated using PTX-resistant 4T1 cells (4T1/PTX cells) in both in vitro and in vivo models.Results: PDPLL NPs had a particle size of 49.6 +/- 5.9 nm and a zeta potential of 7.87 +/- 0.68 mV. The PTX drug loading (DL)% was 2.59%. The siAXL DL was 2.5 mg PDPLL: 10 nmol siAXL. The release of PTX showed sustained release performance. The release of siAXL showed sensitivity for the TME. The NPs were stable in the plasma. The NPs promoted cell uptake by PTX-resistant 4T1 cells (4T1/PTX) and promoted tumor targeting and permeability in vivo. siAXL enhanced the toxicity and apoptosis efficiency of PTX in 4T1/PTX cells, as well as the cycle arrest efficiency caused by PTX. The NPs improved the above effects. In mouse 4T1/PTX orthotopic tumors, the NPs enhanced the sensitization of PTX to siAXL.Conclusion: The PDPLL NP co-delivery system possesses good encapsulating potential not only for PTX but also for siRNA. It can enhance the tumor-targeting effect and overcome the drug resistance of 4T1/PTX both in vitro and in vivo. This system is a potential delivery system for RNAs.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Gemcitabine with cisplatin or paclitaxel in metastatic triple-negative breast cancer
    Hu, Xichun
    Xu, Binghe
    Cai, Li
    Wang, Zhonghua
    Wang, Biyun
    Zhang, Jian
    Teng, Yuee
    Tong, Zhongsheng
    Pan, Yueyin
    Yin, Yongmei
    Wu, Changping
    Jiang, Zefei
    Wang, Xiaojia
    Lou, Guyin
    Liu, Donggeng
    Feng, Jifeng
    Luo, Jianfeng
    Wu, Jiong
    Shao, Zhimin
    Ragaz, Joseph
    CANCER RESEARCH, 2015, 75
  • [22] Pembrolizumab plus Chemotherapy for triple-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1114 - 1114
  • [23] Chemotherapy for Triple-Negative Breast Cancer: Is More Better?
    Mayer, Erica L.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) : 3369 - +
  • [24] Platinum chemotherapy for early triple-negative breast cancer
    Mason, Sofia RE.
    Willson, Melina L.
    Egger, Sam J.
    Beith, Jane
    Dear, Rachel F.
    Goodwin, Annabel
    BREAST, 2024, 75
  • [25] Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer
    Elizabeth, Melendez Solano
    Cristina, Stevens Barron Jazmin
    Christian, Chapa Gonzalez
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (04) : 431 - 439
  • [26] Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer
    Locatelli, Marzia A.
    Curigliano, Giuseppe
    Eniu, Alexandru
    BREAST CARE, 2017, 12 (03) : 152 - 158
  • [27] Pembrolizumab plus chemotherapy in triple-negative breast cancer
    Masuda, Jun
    Ozaki, Yukinori
    Hara, Fumikata
    Kitano, Shigehisa
    Takano, Toshimi
    LANCET, 2021, 398 (10294): : 24 - 24
  • [28] Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy
    Chunai Gong
    Jing Tian
    Zhuo Wang
    Yuan Gao
    Xin Wu
    Xueying Ding
    Lei Qiang
    Guorui Li
    Zhimin Han
    Yongfang Yuan
    Shen Gao
    Journal of Nanobiotechnology, 17
  • [29] Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy
    Gong, Chunai
    Tian, Jing
    Wang, Zhuo
    Gao, Yuan
    Wu, Xin
    Ding, Xueying
    Qiang, Lei
    Li, Guorui
    Han, Zhimin
    Yuan, Yongfang
    Gao, Shen
    JOURNAL OF NANOBIOTECHNOLOGY, 2019, 17 (01)
  • [30] DSTYK Enhances Chemoresistance in Triple-Negative Breast Cancer Cells
    Ogbu, Stella C.
    Rojas, Samuel
    Weaver, John
    Musich, Phillip R.
    Zhang, Jinyu
    Yao, Zhi Q.
    Jiang, Yong
    CELLS, 2022, 11 (01)